20 LATEST RESOURCES (152 INDEXED)
Impacts of Metabolic Disruption, Body Mass Index and Inflammation on Cognitive Function in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine · February 2024
Articles
Annals of General Psychiatry
Psychiatric Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Pharmacovigilance Analysis of Individual Case Safety Reports Submitted to the Eudravigilance Database · January 2024
Articles
International Journal of Clinical Pharmacy
Comparison of Olanzapine-Induced Weight Gain and Metabolism Abnormalities between Topiramate and Vitamin C in Patients with Schizophrenia: A Preliminary Study · May 2023
Articles
Frontiers in Psychiatry
Metabolic Biomarkers of Risperidone-Induced Weight Gain in Drug-Naive Patients with Schizophrenia · April 2023
Articles
Frontiers in Psychiatry
Olanzapine and Weight Loss in Early-Onset Schizophrenia · April 2023
Articles
Primary Care Companion for CNS Disorders
Acetylsalicylic Acid Effect in Colorectal Cancer Taking into Account the Role of Tobacco, Alcohol and Excess Weight · February 2023
Articles
International Journal of Environmental Research and Public Health
Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention: A Randomized Clinical Trial · September 2022
Articles
Mayo Clinic Proceedings: Innovations, Quality and Outcomes
A Systematic Review of Clinical Trials on Lumateperone and Its Effects on Body Weight · September 2022
Abstracts
Journal of Clinical Psychopharmacology
Antioxidant Enzymes and Weight Gain in Drug-Naive First-Episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study · August 2022
Articles
NCBI>Current Neuropharmacology
Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: Two Randomized Clinical Trials · May 2022
Articles
Schizophrenia Bulletin
Changes in Physical Activity during a One-Year Weight Loss Trial with Liraglutide vs Placebo in Participants with Knee Osteoarthritis: Secondary Analyses of a Randomised Controlled Trial · March 2022
Articles
Osteoarthritis and Cartilage Open
Opioid Antagonism Mitigates Antipsychotic-Associated Weight Gain: Focus on Olanzapine · March 2022
Articles
CNS Spectrums
Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study · December 2021
Articles
International Journal of Environmental Research and Public Health
A Double-Blind, Placebo-Controlled Trial of Bupropion Add-On to Olanzapine or Risperidone in Overweight Individuals with Schizophrenia · November 2021
Abstracts
Journal of Clinical Psychopharmacology
Metformin in the Management of Antipsychotic-Induced Weight Gain in Adults with Psychosis: Development of the First Evidence-Based Guideline Using GRADE Methodology · September 2021
Articles
Evidence-Based Mental Health
The Association between BDNF Levels and Risperidone-Induced Weight Gain Is Dependent on the BDNF Val66Met Polymorphism in Antipsychotic-Naive First Episode Schizophrenia Patients: A 12-Week Prospective Study · September 2021
Articles
Translational Psychiatry
Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia · July 2021
Articles
International Journal of General Medicine
Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-Desmethyl Olanzapine in Inpatients with Schizophrenia · May 2021
Abstracts
Journal of Clinical Psychopharmacology
Effect of Bifidobacterium on Olanzapine-Induced Body Weight and Appetite Changes in Patients with Psychosis · May 2021
Abstracts
Psychopharmacology
Weight Gain in Veterans Taking Duloxetine, Pregabalin, or Both for the Treatment of Neuropathy · May 2021
Articles
NCBI>Federal Practitioner